Doyal Kalita Banned for 10 Years from US Drug Imports
Published Date: 8/19/2025
Notice
Summary
The FDA is banning Doyal Kalita from importing any drugs into the U.S. for 10 years because he was convicted of serious crimes related to drug importation. He had a chance to fight this but didn’t respond, so the ban starts on June 26, 2025. This means no drug imports from him for a decade, keeping the market safer and cleaner.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Individual Debarred from Drug Imports
The FDA barred Doyal Kalita from importing or offering for import any drug into the United States for 10 years. The ban begins June 26, 2025 because he was convicted of two federal felony counts related to drug importation, and he did not request a hearing.
FDA Action Aims to Protect Consumers
The FDA says the debarment helps keep the drug market safer and cleaner by preventing someone convicted of importation-related felonies from importing drugs for 10 years starting June 26, 2025. That action is intended to reduce the risk of unsafe or illegal drugs entering the U.S.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2025-15786, Determination That RIFADIN (Rifampin) Capsules, 150 Milligrams and 300 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA says RIFADIN capsules (150 mg and 300 mg) weren’t pulled from the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they meet safety rules, especially about tiny impurities. Patients and drug makers can keep counting on these meds without any sudden changes or extra costs.
Next: 2025-15788, Administrative Declaration of a Disaster for the State of Missouri
Missouri just got hit hard by storms, flooding, and hail, so the government declared it a disaster on August 13, 2025. This means people and businesses affected can get special help and money to recover faster. If you live in Missouri, expect quicker aid and support to fix damage and get back on your feet.